Literature DB >> 22822101

Effects of phosphate on vascular function under normal conditions and influence of the uraemic state.

Isabelle Six1, Julien Maizel, Fellype C Barreto, Ashraf Y Rangrez, Sébastien Dupont, Michel Slama, Christophe Tribouilloy, Gabriel Choukroun, Jean Claude Mazière, Stefanie Bode-Boeger, Jan T Kielstein, Tilman B Drüeke, Ziad A Massy.   

Abstract

AIMS: Increased serum phosphorus levels are associated with cardiovascular disease in patients with chronic kidney disease (CKD) and in the general population. High phosphate levels may play a direct role in vascular dysfunction. We investigated here the effects of phosphate loading and of the phosphate binder sevelamer-HCl on vascular function. METHODS AND
RESULTS: CKD and non-CKD C57/BL6 mice were used to study the effects of CKD, phosphate, and sevelamer-HCl on vascular function and structure. In vitro, phosphate exhibited a direct vasoconstrictor effect on aortic rings. This effect was smaller in vessels from CKD than non-CKD mice and it was abolished by reactive oxygen species inhibitor dimethylthiourea. A high-phosphate diet (1.3%) increased phenylephrine-induced contraction and lowered acetylcholine-induced relaxation of aortic rings ex vivo, both in non-CKD and CKD mice. It also induced endothelial cell detachment. Sevelamer-HCl exposure in vitro normalized the endothelial dysfunction induced by 3.0 mM phosphate and restored endothelial integrity. Sevelamer-HCl treatment of CKD mice under normal diet (0.65% phosphate) improved the endothelial dysfunction, aortic systolic expansion rate, and pulse wave velocity, and it reduced the endothelial expression of adhesion molecules.
CONCLUSION: Changes in extracellular phosphorus concentrations may directly modulate vascular function and thereby modulate the vascular smooth muscle response to physiological or pathological stimuli in normal and CKD mice. Whether serum phosphorus lowering and/or dietary phosphate restriction can improve arterial function in humans remains to be established.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22822101     DOI: 10.1093/cvr/cvs240

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  39 in total

Review 1.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

Review 2.  Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.

Authors:  David M Charytan; Steven Fishbane; Jolanta Malyszko; Peter A McCullough; David Goldsmith
Journal:  Am J Kidney Dis       Date:  2015-02-26       Impact factor: 8.860

Review 3.  Chronic kidney disease in the pathogenesis of acute ischemic stroke.

Authors:  Bharath Chelluboina; Raghu Vemuganti
Journal:  J Cereb Blood Flow Metab       Date:  2019-08-01       Impact factor: 6.200

Review 4.  Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

Review 5.  Crosstalk between the nervous system and the kidney.

Authors:  Shinji Tanaka; Mark D Okusa
Journal:  Kidney Int       Date:  2019-11-22       Impact factor: 10.612

Review 6.  Stop chronic kidney disease progression: Time is approaching.

Authors:  Usama Abdel Azim Sharaf El Din; Mona Mansour Salem; Dina Ossama Abdulazim
Journal:  World J Nephrol       Date:  2016-05-06

7.  Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.

Authors:  Radwa El Borolossy; Lamia Mohamed El Wakeel; Ihab El Hakim; Nagwa Sabri
Journal:  Pediatr Nephrol       Date:  2015-09-29       Impact factor: 3.714

8.  A Controlled Increase in Dietary Phosphate Elevates BP in Healthy Human Subjects.

Authors:  Jaber Mohammad; Roberto Scanni; Lukas Bestmann; Henry N Hulter; Reto Krapf
Journal:  J Am Soc Nephrol       Date:  2018-07-18       Impact factor: 10.121

9.  Serum phosphate and cognitive function in older men.

Authors:  Yelena Slinin; Tien Vo; Brent C Taylor; Anne M Murray; John Schousboe; Lisa Langsetmo; Kristine Ensrud
Journal:  Int J Geriatr Psychiatry       Date:  2017-03-22       Impact factor: 3.485

10.  A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).

Authors:  Nigel D Toussaint; Eugenia Pedagogos; Nicole M Lioufas; Grahame J Elder; Elaine M Pascoe; Sunil V Badve; Andrea Valks; Geoffrey A Block; Neil Boudville; James D Cameron; Katrina L Campbell; Sylvia S M Chen; Randall J Faull; Stephen G Holt; Dana Jackson; Meg J Jardine; David W Johnson; Peter G Kerr; Kenneth K Lau; Lai-Seong Hooi; Om Narayan; Vlado Perkovic; Kevan R Polkinghorne; Carol A Pollock; Donna Reidlinger; Laura Robison; Edward R Smith; Robert J Walker; Angela Yee Moon Wang; Carmel M Hawley
Journal:  J Am Soc Nephrol       Date:  2020-09-11       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.